| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal HST17: Odevixibat for treating progressive familial intrahepatic cholestasis |
|
Medicine details |
|
| Medicine name | odevixibat (Bylvay®) |
| Formulation | 200 µg, 400 µg, 600 µg and 1200µg hard capsules |
| Reference number | 3443 |
| Indication | Treatment of progressive familial intrahepatic cholestasis (PFIC) in patients aged 6 months or older |
| Company | Albireo Pharma Inc |
| BNF chapter | Gastro-intestinal system |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 18/06/2021 |
| NICE guidance | HST17: Odevixibat for treating progressive familial intrahepatic cholestasis |